Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on BriaCell Therapeutics (BCT – Research Report), retaining the price target of $32.00.
Emily Bodnar’s rating is based on several key factors that highlight the potential of BriaCell Therapeutics. The company is making significant progress in its Bria-IMT Phase 3 trial for advanced/metastatic breast cancer, with enrollment accelerating and over 75 patients already enrolled. The trial’s design includes an interim analysis, and if successful, could lead to full FDA approval and marketing authorization. This creates a significant milestone expected within the next year.
Furthermore, BriaCell’s Phase 2 data shows promising overall survival rates in different breast cancer subtypes, suggesting benefits comparable to existing therapies but with a potentially better safety profile. The company’s financials also indicate a strategic focus on managing expenses, with a notable reduction expected in FY2025. These elements combined suggest a strong potential for growth and success, justifying the Buy rating.